Navigation Links
SemBioSys to present at the Needham & Company Biotechnology and Medical Technology Conference
Date:6/4/2008

TSX symbol: SBS

CALGARY, June 4 /PRNewswire-FirstCall/ - SemBioSys Genetics Inc. (TSX:SBS), a biotechnology company developing a portfolio of therapeutic proteins for metabolic and cardiovascular diseases, today announced that Andrew Baum, president & CEO of the company, will present a corporate update at the Needham & Company, LLC Seventh Annual Biotechnology and Medical Technology Conference. The presentation is scheduled on Wednesday, June 11 at 2:30 p.m., at the New York Palace Hotel.

Interested parties may access a live webcast of the presentation by visiting the company's website at http://www.sembiosys.com. Please connect at least 15 minutes prior to the presentation to ensure adequate time for any software download that may be required to join the webcast. An audio archive of the presentation will be available for approximately 30 days.

About SemBioSys Genetics Inc.

Calgary, Alberta-based SemBioSys Genetics Inc. is a biotechnology company developing protein-based pharmaceuticals for metabolic and cardiovascular diseases. The Company's lead pharmaceutical candidates, produced in the plant host safflower, are recombinant human insulin to serve the rapidly expanding global diabetes market and Apo AI, a next generation cardiovascular drug. In addition to its pharmaceutical products, SemBioSys' subsidiary, Botaneco, develops and supplies proprietary specialty ingredients to the personal care industry. More information is available at http://www.sembiosys.com.


'/>"/>
SOURCE SemBioSys Genetics Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. SemBioSys updates Apo AI development program
2. SemBioSys to present insulin data at the Seventh Annual Diabetes Technology Meeting
3. SemBioSys announces 2007 third quarter results
4. SemBioSys signs option agreement for safflower-produced food ingredient
5. SemBioSys to present at the 10th Annual BIO CEO & Investor Conference
6. SemBioSys awarded key patent for the production of oleosome emulsions by the European Patent Office
7. SemBioSys GLA Partner Enters Strategic Alliance for the Sales and Marketing of GLA-Rich Safflower Oil
8. SemBioSys announces 2007 financial and operational results
9. SemBioSys initiates toxicology study for safflower-produced insulin
10. SemBioSys receives milestone payments from AVAC Ltd.
11. SemBioSys announces first quarter 2008 financial and operational results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/16/2017)... PARSIPPANY, N.J. (PRWEB) , ... July 16, 2017 ... ... products, laboratory equipment and analytical instruments announced the launch of its new line ... shakers are ideal for applications that require CO2 and humidity for optimal cell ...
(Date:7/14/2017)... ... July 14, 2017 , ... ... . Sonic Manufacturing Technologies has installed a solar system on its roof top. ... period,” the President of Sonic, Kenneth Raab stated. The company’s proud history of ...
(Date:7/14/2017)... ... July 13, 2017 , ... LGC Maine Standards ... US FDA 510 (k) clearance for use on Siemens Sysmex® CS-2500 System analyzers. ... D-Dimer kit, prepared using the CLSI EP06-A “equal delta” sample preparation, offers five ...
(Date:7/13/2017)... (PRWEB) , ... July 13, 2017 , ... Thousands of ... and August for the National Aeromodeling Championships (Nats). Pilots come to Muncie to compete ... to earn spots on US teams that participate in world championships. , RC Pylon ...
Breaking Biology Technology:
(Date:4/5/2017)... April 5, 2017  The Allen Institute for Cell ... Explorer: a one-of-a-kind portal and dynamic digital window into ... data, the first application of deep learning to create ... cell lines and a growing suite of powerful tools. ... these and future publicly available resources created and shared ...
(Date:4/5/2017)... 2017 KEY FINDINGS The global ... a CAGR of 25.76% during the forecast period of ... factor for the growth of the stem cell market. ... MARKET INSIGHTS The global stem cell market is ... geography. The stem cell market of the product is ...
(Date:4/3/2017)... 3, 2017  Data captured by IsoCode, ... detected a statistically significant association between the ... treatment and objective response of cancer patients ... predict whether cancer patients will respond to ... well as to improve both pre-infusion potency testing ...
Breaking Biology News(10 mins):